entertainment -WSS

entertainment

author：entertainment 2025-09-30 22:03:50 - browse：3319

inflamed intestine on a dark blue background — biotech coverage from STAT — Adobe

What happens after you close a nearly $11 billion acquisition?

Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future.

Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer. This “summer of discovery,” as McKenna called it, brought him back to the immune system. Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： CDC recommends RSV monoclonal antibody for infants

entertainment

WSS

The cancer stories no one wants to hear

FDA approves Sage Therapeutics’ rapid

FDA approves Sage Therapeutics’ rapid

Oral obesity drug from Viking Therapeutics hits key early target

Group behind ProMed defends move to subscription

The a glaring gap in research on serious mental illness and primary care

knowledge

entertainment

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flint parents haunted by uncertainty, fears of lead poisoning

Moonlake's readout produced a cash windfall. Risks remain

Scientific mystery highlights the blind spots in genomics databases

What does generative AI mean for health care? We asked experts

Scientists uncover potential path to treating deadly childhood tumor

Psychedelics group wrestles with new pharma identity

FDA approves Sage Therapeutics’ rapid

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare slashes safety net hospital payments by nearly $1 billion

hotspot

Late stage cancers on the rise after pandemic delayed screenings

How to ethically and practically extend health care to all

Researchers test human milk's ability to repair gut microbiome

U.K. decision on ALS drug has neurologists, advocates up in arms

Young boy dies in trial for Pfizer Duchenne gene therapy

Young boy dies in trial for Pfizer Duchenne gene therapy

leisure time

focus

entertainment

leisure time